HOME > About Walvax > Product

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed

 Market Approval time
The product was on market officially in July 27, 2015
 Introduction
DESCRIPTION
This vaccine is a milky-white suspension prepared by the adsorption of bulks of Bordetella pertussis antigens, diphtheria toxoid and tetanus toxoid onto aluminum hydroxide. Upon storage, a white deposit and clear supernatant can be observed.
One dose of 0.5ml contains:
Bordetella pertussis antigens………………………..…not less than 4.0 IU
Diphtheria toxoid………………………………………………not less than 30 IU
Tetanus toxoid…………………………………………………not less than 40 IU
Excipients:Aluminum hydroxide, sodium chloride, sodium hydrogen phosphate, sodium dihydrogen phosphat

INDICATIONS
The vaccine is indicated for active immunization for the prevention of diphtheria, tetanus and pertussis in individuals from the age of three months to six years.
The vaccine is not to be used for the treatment of disease caused by Bordetella pertussis, Corynebacterium diphtheriae or Clostridium tetani infections.

ADMINISTRATION AND DOSAGE
The vaccine is for intramuscular injection at the buttock or in the deltoid region.Each singe human dose is 0.5ml.
Primary immunization consisting three injections shall be carried out from 3 months till 12 months of age, 0.5 ml per injection at intervals of 4-6 weeks. A booster of 0.5ml is recommended at the age of 18-24 months.

PACKAGING
Vial. 1 dose.

SHELF LIFE
24 months.
 

免责声明: 本站资料及图片来源互联网文章,本网不承担任何由内容信息所引起的争议和法律责任。所有作品版权归原创作者所有,与本站立场无关,如用户分享不慎侵犯了您的权益,请联系我们告知,我们将做删除处理!